Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Interest & Investment Income (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Interest & Investment Income for 8 consecutive years, with $901000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest & Investment Income fell 51.84% year-over-year to $901000.0, compared with a TTM value of $3.9 million through Sep 2025, down 35.13%, and an annual FY2024 reading of $5.8 million, up 25.91% over the prior year.
  • Interest & Investment Income was $901000.0 for Q3 2025 at X4 Pharmaceuticals, up from $665000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.9 million in Q3 2024 and bottomed at $2000.0 in Q1 2021.
  • Average Interest & Investment Income over 5 years is $693210.5, with a median of $835000.0 recorded in 2023.
  • The sharpest move saw Interest & Investment Income plummeted 99.32% in 2021, then soared 27733.33% in 2023.
  • Year by year, Interest & Investment Income stood at $3000.0 in 2021, then surged by 6500.0% to $198000.0 in 2022, then soared by 629.8% to $1.4 million in 2023, then fell by 12.32% to $1.3 million in 2024, then decreased by 28.89% to $901000.0 in 2025.
  • Business Quant data shows Interest & Investment Income for XFOR at $901000.0 in Q3 2025, $665000.0 in Q2 2025, and $1.0 million in Q1 2025.